Targeting the insulin‐like growth factor‐1 receptor by picropodophyllin for lung cancer chemoprevention

Publisher： John Wiley & Sons Inc

E-ISSN： 1098-2744|54|S1|E129-E137

ISSN： 0899-1987

Source： Molecular Carcinogenesis, Vol.54, Iss.S1, 2015-06, pp. : E129-E137

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Apigenin suppresses insulin‐like growth factor I receptor signaling in human prostate cancer: An in vitro and in vivo study

By  

Molecular Carcinogenesis, Vol. 48, Iss. 3, 2009-03 ,pp. : 243-252

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inhibition of lung adenocarcinoma cells by insulin‐like growth factor‐I receptor and Kirsten rat sarcoma mutations: A mutation analysis with antisense oligodeoxynucleotide

By  

Thoracic Cancer, Vol. 6, Iss. 3, 2015-05 ,pp. : 260-268

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung

By  

Thoracic Cancer, Vol. 6, Iss. 3, 2015-05 ,pp. : 319-326

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pitfalls in diagnosis with the use of circulating tumor‐derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 171-174

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subsequent treatment of epidermal growth factor receptor‐tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 678-686

John Wiley & Sons Inc

Access to resources Recommend Favorite